Volume 88, Issue 6, Pages (December 2015)

Slides:



Advertisements
Similar presentations
Volume 83, Issue 2, Pages (February 2013)
Advertisements

Volume 54, Issue 2, Pages (August 1998)
Beta blockers in the management of chronic kidney disease
Plasma sodium and hypertension
Volume 74, Issue 7, Pages (October 2008)
A powerful new agonist: flooding the system with growth hormone
Volume 88, Issue 6, Pages (December 2015)
Anemia management in chronic kidney disease
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
Volume 83, Issue 5, Pages (May 2013)
Volume 83, Issue 3, Pages (March 2013)
Pieter Evenepoel, Myles Wolf  Kidney International 
High prevalence of chronic kidney disease in Thailand
Shining light on vitamin D trials in chronic kidney disease
Prehypertension and chronic kidney disease: the ox or the plow?
Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007  Joanna M. Smith, Susan A. Mott,
Reassessment of the care of the patient with chronic kidney disease
John P. Middleton, Patrick H. Pun  Kidney International 
Volume 88, Issue 2, Pages (August 2015)
Yasuhiro Hamada, Masafumi Fukagawa  Kidney International 
Volume 85, Issue 3, Pages (March 2014)
Volume 79, Issue 7, Pages (April 2011)
Is there a pharmacologic basis for combination renin axis blockade?
Jeffrey C. Fink, Glenn M. Chertow  Kidney International 
Volume 70, Pages S21-S25 (December 2006)
James F. List, Jean M. Whaley  Kidney International 
The Stunned β Cell: A Brief History
Volume 68, Issue 4, Pages (October 2005)
George A. Kaysen, Burl R. Don
Volume 71, Issue 2, Pages (January 2007)
Ian H. de Boer, Rajnish Mehrotra  Kidney International 
Comorbidity and confounding in end-stage renal disease
D. Batlle, P. Ramadugu, M.J. Soler  Kidney International 
Proinflammatory effects of iron sucrose in chronic kidney disease
Acute myocardial infarction in patients with chronic kidney disease: how are the most vulnerable patients doing?  Gautam R. Shroff, Charles A. Herzog 
Volume 74, Issue 3, Pages (August 2008)
Volume 70, Issue 11, Pages (December 2006)
Volume 83, Issue 5, Pages (May 2013)
The epidemiology of chronic kidney disease
Use of vitamin D in chronic kidney disease patients
H. Wong, K. Mylrea, J. Feber, A. Drukker, G. Filler 
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease  S. Bianchi, R. Bigazzi, V.M. Campese 
The calcium–phosphorus in guidelines for CKD-MBD
Blood pressure targets in hemodialysis patients
Altered tryptophan metabolism and CKD-associated fatigue
Volume 73, Issue 12, Pages (June 2008)
Francesco Locatelli, Lucia Del Vecchio  Kidney International 
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
Methods for guideline development
Volume 85, Issue 1, Pages 3-4 (January 2014)
The global challenge of chronic kidney disease
Nephrology Crossword: Glomerulonephritis
A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease  S. Susan Hedayati, Venkata Yalamanchili,
Vitamin D in chronic kidney disease: is the jury in?
Cardio-Kidney-Damage: a unifying concept
Phosphate binders on iron basis: A new perspective?
Volume 80, Issue 10, Pages (November 2011)
Volume 70, Issue 2, Pages (July 2006)
Volume 80, Issue 10, Pages (November 2011)
Volume 60, Issue 6, Pages (December 2001)
The hypothesis that abnormal BH4 metabolism impairs kidney function
Volume 75, Issue 9, Pages (May 2009)
Thomas C. Dowling, Reginald F. Frye, Donald S. Fraley, Gary R. Matzke 
Volume 138, Issue 4, Pages (April 2010)
Volume 74, Issue 10, Pages (November 2008)
O.M. Gutiérrez, T. Isakova, D.L. Andress, A. Levin, M. Wolf 
The prevalence of hematologic and metabolic abnormalities during chronic kidney disease stages in different ethnic groups  S.J. Barbour, L. Er, O. Djurdjev,
Volume 71, Issue 2, Pages (January 2007)
Volume 55, Issue 5, Pages (May 1999)
Peter Stenvinkel, Olof Heimbürger, Catherine H. Tuck, Lars Berglund 
Presentation transcript:

Volume 88, Issue 6, Pages 1419-1426 (December 2015) Insulin sensitivity of muscle protein metabolism is altered in patients with chronic kidney disease and metabolic acidosis  Giacomo Garibotto, Antonella Sofia, Rodolfo Russo, Ernesto Paoletti, Alice Bonanni, Emanuele L. Parodi, Francesca Viazzi, Daniela Verzola  Kidney International  Volume 88, Issue 6, Pages 1419-1426 (December 2015) DOI: 10.1038/ki.2015.247 Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 1 The effect of insulin on forearm skeletal muscle glucose uptake in patients with chronic kidney disease (CKD) (n=7) and controls (n=7). The 0.035mU/kg per min insulin infusion rate resulted in significant increases of glucose uptake of ∼3–4-fold in control subjects. The effect of local insulin was reduced by ~40% in patients with CKD. Values are mean±s.e.m. aStatistically significant differences (P≤0.02) between basal and insulin-infused periods. bStatistically significant differences (P≤0.03) between patients with CKD and controls. Kidney International 2015 88, 1419-1426DOI: (10.1038/ki.2015.247) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 2 Effect of insulin at 0.01and 0.035mU/kg per min on forearm muscle net protein balance. (a, b) In control subjects, the negative net protein balance observed in the basal, postabsorptive state was markedly decreased by insulin at both 0.01 (n=5) and 0.035mU/kg per min (n=7). (a) Contrariwise, no effect of low-dose (0.01mU/kg per min) insulin infusion was observed in patients with chronic kidney disease (CKD) (n=5). (b) At higher insulin infusion rates (0.035mU/kg per min) net protein balance declined in patients (n=7) similarly to control subjects. Values are mean±s.e.m. aStatistically significant differences (P≤0.01 or less) between basal and insulin-infused periods. bStatistically significant differences (P≤0.03 or less) between patients with CKD and controls. Kidney International 2015 88, 1419-1426DOI: (10.1038/ki.2015.247) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 3 Effect of insulin at 0.01and 0.035mU/kg/min on forearm muscle protein degradation. (a) In control subjects the 0.01mU/kg per min insulin infusion produced a significant ~31–34% decrease of protein degradation while it was only modestly influenced in patients with chronic kidney disease (CKD) (n=5); (b) A similar suppression of protein degradation in response to the higher insulin infusion rates was observed in control subjects (n=7) and patients with CKD (n=7). Values are mean±s.e.m. aStatistically significant differences (P≤0.01) between basal and insulin-infused periods. Kidney International 2015 88, 1419-1426DOI: (10.1038/ki.2015.247) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 4 Effect of insulin at 0.01and 0.035mU/kg per min on forearm muscle protein synthesis. (a, b) No change in muscle protein synthesis was observed at both insulin infusion rates in controls and patients with chronic kidney disease (CKD). NS, nonsignificant. Kidney International 2015 88, 1419-1426DOI: (10.1038/ki.2015.247) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 5 Dose–response relationships between net protein balance across the forearm and insulin levels. To determine the dose–response characteristics for the effect of insulin on muscle protein metabolism, the net balance of phenylalanine across the forearm was plotted versus the corresponding steady-state plasma insulin concentrations (only the 100 and 120min infusion data point considered) during insulin infusion. The fitted curve is a nonlinear least squares best fit to a logarithmic function. In control subjects, net protein balance decreased steeply from -17nmol/min per 100ml in the basal, postabsorptive state to -8nmol/min per 100ml when insulin concentrations were raised to 30μU/ml. With further increases in insulin concentrations to ~100μU/ml, net protein balance decreased only to -5nmol/min per 100ml. Thus, the maximal effect of insulin occurred at insulin concentrations between 15 and 30μU/ml. In CKD patients the insulin response was shifted downward with higher net protein balance at moderate hyperinsulinemia. The curve of insulin sensitivity of protein balance in patients with chronic kidney disease (CKD) overlapped with the same curve obtained in controls in the high insulin physiological range. Kidney International 2015 88, 1419-1426DOI: (10.1038/ki.2015.247) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 6 The design of the study. Kidney International 2015 88, 1419-1426DOI: (10.1038/ki.2015.247) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 7 Plasma mass percent enrichment (MPE) of phenylalanine at study time points. CKD, chronic kidney disease. Kidney International 2015 88, 1419-1426DOI: (10.1038/ki.2015.247) Copyright © 2015 International Society of Nephrology Terms and Conditions